SCHEMBL4833491

SCHEMBL4833491

NC1c2ccsc2N=CN1c1ccc(NC(=O)/C=C/c2ccccc2Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.49
▸ MAPT P10636 10/20 0.49
▸ RAB9A P51151 7/20 0.49
▸ NPC1 O15118 5/20 0.49
▸ MAOB P27338 2/20 0.49
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KMT2A Q03164 9/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MEN1 O00255 7/20 0.46
▸ LMNA P02545 3/20 0.46
▸ HTT P42858 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ TP53 P04637 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ THRB P10828 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833292 0.87 EGFR (0.46) MAOAMAPTRAB9ANPC1MAOB
SCHEMBL4834154 0.84 MEN1 (0.50) MAOAMAPTRAB9ANPC1MAOB
SCHEMBL4826281 0.75 RAB9A (0.48) MAPTRAB9ANPC1KMT2AKDM4E
SCHEMBL4834612 0.74 BAZ1A (0.41) MAPTNPC1KMT2AKDM4EMEN1
SCHEMBL4829077 0.74 NPY2R (0.43) KMT2AMEN1HDAC1HDAC8HDAC6
SCHEMBL4831067 0.74 DDX3X (0.44) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL4829300 0.73 HDAC1 (0.43) MAPTRAB9ANPC1CYP2C9CYP2C19
SCHEMBL4829269 0.72 KCNQ2 (0.50) LMNAHTTSMN1; SMN2ALDH1A1TP53
SCHEMBL4833486 0.70 MAPT (0.50) MAOAMAPTRAB9ANPC1MAOB
SCHEMBL4833496 0.70 MAPT (0.50) MAOAMAPTRAB9ANPC1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAOA 2677/4885MAPT 2499/4885RAB9A 3248/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAOA 3188/4885MAPT 2424/4885RAB9A 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback